

REGISTERED NUMBER: 08758564 (England and Wales)

Unaudited Financial Statements for the Year Ended 30 November 2017

for

Arc Pharma (UK) Limited

Aequitas
Chartered Accountants
Elthorne Gate
64 High Street
Pinner
HA5 5QA

**Contents of the Financial Statements
for the Year Ended 30 November 2017**

	Page
Company Information	1
Balance Sheet	2
Notes to the Financial Statements	4

Arc Pharma (UK) Limited

**Company Information
for the Year Ended 30 November 2017**

DIRECTORS:

Mr S Patel
Mr AJ Patel
Mrs SK Pipaliya

REGISTERED OFFICE:

3 Admiral House
Cardinal Way
Harrow
HA3 5TE

REGISTERED NUMBER:

08758564 (England and Wales)

ACCOUNTANTS:

Aequitas
Chartered Accountants
Elthorne Gate
64 High Street
Pinner
HA5 5QA

Balance Sheet
30 November 2017

	Notes	30.11.17 £	£	30.11.16 £	£
FIXED ASSETS					
Tangible assets	4		131,937		58,062
CURRENT ASSETS					
Debtors	5	136,830		115,986	
Cash at bank and in hand		<u>34,332</u>		<u>100</u>	
		171,162		116,086	
CREDITORS					
Amounts falling due within one year	6	<u>301,397</u>		<u>263,028</u>	
NET CURRENT LIABILITIES			<u>(130,235)</u>		<u>(146,942)</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			1,702		(88,880)
PROVISIONS FOR LIABILITIES					
			<u>772</u>		<u>-</u>
NET ASSETS/(LIABILITIES)			<u>930</u>		<u>(88,880)</u>
CAPITAL AND RESERVES					
Called up share capital			100		100
Retained earnings			<u>830</u>		<u>(88,980)</u>
SHAREHOLDERS' FUNDS			<u>930</u>		<u>(88,880)</u>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 November 2017.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 November 2017 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.
- (b)

The notes form part of these financial statements

Balance Sheet - continued
30 November 2017

The financial statements have been prepared and delivered in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors on 8 May 2018 and were signed on its behalf by:

Mr AJ Patel - Director

**Notes to the Financial Statements
for the Year Ended 30 November 2017**

1. STATUTORY INFORMATION

Arc Pharma (UK) Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover represents revenue generated from the laboratory testing and consultancy services and is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discount, settlement discounts and volume rebates.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery	- 25% on reducing balance
Fixtures and fittings	- 25% on reducing balance

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Notes to the Financial Statements - continued
for the Year Ended 30 November 2017

2. ACCOUNTING POLICIES - continued

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 8 (2016 - 5) .

4. TANGIBLE FIXED ASSETS

	Plant and machinery £	Fixtures and fittings £	Totals £
COST			
At 1 December 2016	111,064	23,406	134,470
Additions	116,548	1,306	117,854
At 30 November 2017	227,612	24,712	252,324
DEPRECIATION			
At 1 December 2016	62,876	13,532	76,408
Charge for year	41,184	2,795	43,979
At 30 November 2017	104,060	16,327	120,387
NET BOOK VALUE			
At 30 November 2017	123,552	8,385	131,937
At 30 November 2016	48,188	9,874	58,062

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	30.11.17 £	30.11.16 £
Trade debtors	131,143	78,377
Other debtors	3,750	3,750
Deferred tax asset	-	21,904
Prepayments and accrued income	1,937	11,955
	<u>136,830</u>	<u>115,986</u>

Included within trade debtors above are factored debts of £131,143 which remain outstanding as at the balance sheet date.

Notes to the Financial Statements - continued
for the Year Ended 30 November 2017

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	30.11.17	30.11.16
	£	£
Bank loans and overdrafts (see note 7)	53,369	73,953
Trade creditors	136,799	109,444
Social security and other taxes	1,626	1,493
Wages control account	-	1,230
Pensions	84	-
VAT	12,009	532
Other creditors	87,635	72,101
Income in advance	1,275	1,275
Accruals and deferred income	8,600	3,000
	<u>301,397</u>	<u>263,028</u>

7. LOANS

An analysis of the maturity of loans is given below:

	30.11.17	30.11.16
	£	£
Amounts falling due within one year or on demand:		
Bank overdrafts	53,369	64,305
Bank loans	-	9,648
	<u>53,369</u>	<u>73,953</u>

8. SECURED DEBTS

The following secured debts are included within creditors:

	30.11.17	30.11.16
	£	£
Bank overdrafts	53,369	64,305
Bank loans	-	9,648
	<u>53,369</u>	<u>73,953</u>

The bank loans and overdrafts falling due within one year are secured by a fixed and floating charges over the assets of the company.

**Notes to the Financial Statements - continued
for the Year Ended 30 November 2017**

9. RELATED PARTY DISCLOSURES

Included within other creditors is £31,200 (2016:£26,600) owed to Ayniry Ltd, a company in which Mr A Patel is a director and shareholder.

Other creditors also includes £45,501 (2016:45,501) owed to the parent company, Pharmadose Ltd in which Mr S Patel is a director and shareholder.

The loans are repayable on demand and free of interest.

During the year the company paid consultancy fees of £32,500 and 44,805 to Ayniry Ltd and Pharmadose Ltd respectively. The transactions are bona fide and conducted on normal commercial terms and on an arms-length basis.

10. ULTIMATE CONTROLLING PARTY

The ultimate parent company is Pharmadose Limited, a company incorporated in England. Pharmadose Limited owns 51% of the issued share capital of Arc Pharma (UK) Limited.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.